Newcells Biotech receive £5m to boost liver and lung condition research
February 25, 2021Stem cell model specialists Newcells Biotech has received £5.25 million in new funding to further their growth in 3D tissue …
NICE issues draft guidance recommending sapropterin for PKU in children
February 25, 2021BioMarin, NICE, PKU
NICE has issued draft guidance which recommends BioMarin’s Kuvan (sapropterin) at a dose of up to 10 mg/kg for treating phenylketonuria …
New research article confirms role of masitinib as a potential pancreatic cancer therapy
February 25, 2021AB Sciences, Cancer, masitinib
A recently published, peer-reviewed research article has concluded that the inhibition of mast cells with AB Science’s masitinib could represent …
UC San Diego School of Medicine researchers treat atopic dermatitis with bacteriotherapy
February 24, 2021Research and Development atopic dermatitis, eczema
Researchers at the University of California San Diego School of Medicine have identified a universal strain of bacteria derived from …
Sanofi and SIRION collaborate on AAV vector development to treat serious diseases
February 24, 2021Research and Development AAV vectors, SIRION, Sanofi
SIRION Biotech and Sanofi have entered into an agreement to develop effective medicines for illnesses impacting major human organs.
QIAGEN and INOVIO to develop diagnostic tests for cervical dysplasia treatment
February 24, 2021Research and Development Inovio, Qiagen, cervical dysplasia
QIAGEN and INOVIO Pharmaceuticals have extended their collaboration to develop a new diagnostic test which identifies the women most likely …
FDA halts studies for bluebird bio’s sickle cell therapy LentiGlobin
February 24, 2021Research and Development Bluebird Bio, FDA, sickle cell disease
The FDA has put bluebird bio’s LentiGlobin gene therapy programme for sickle cell disease (SCD) on clinical hold, following Suspected …
RedHill Biopharma to expand COVID-19 opaganib trial to US
February 24, 2021Research and Development COVID-19, RedHill Biopharma
RedHill Biopharma has announced its plans to expand the company’s global Phase II/III study of opaganib in patients with severe …
Microsoft and UCB collaborate to treat immunological and neurological diseases
February 23, 2021Manufacturing and Production Microsoft, UCB, artificial intelligence
UCB and Microsoft have agreed a new multi-year collaboration to discover new medicines by combining UCB’s drug discovery and development …
Otonomy’s OTIVIDEX ear medicine falls short in Phase III study
February 23, 2021Manufacturing and Production meniere's disease, otividex, otonomy
Otonomy’s OTIVIDEX treatment for Meniere’s disease has failed to meet its primary endpoint in its Phase III trial, the company …
Novo Holdings acquires pharma research company Altasciences
February 23, 2021Manufacturing and Production Novo Holdings, altasciences, pharma research
Novo Holdings has agreed a deal to buy Canadian pharmaceutical research company Altasciences from Audax Private Equity, the two companies …
Dynavax’s hepatitis B vaccine gets EU approval
February 23, 2021Manufacturing and Production EU, Vaccine, hepatitis B
The European Commission (EC) has granted marketing authorisation Dynavax Technologies Corporation’s HEPLISAV B vaccine for the active immunisation against hepatitis …
FDA approves Regeneron & Sanofi’s Libtayo for advanced non-small cell lung cancer
February 23, 2021Manufacturing and Production Cancer, Sanofi
The FDA has approved Regeneron & Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) for the first-line treatment of patients with advanced non-small …
GSK and Sanofi to begin new Phase II trial of their COVID-19 vaccine
February 22, 2021Sales and Marketing COVID, COVID Vaccine, COVID-19, GSK, Sanofi
GlaxoSmithKline (GSK) and Sanofi are set to begin a new Phase II study of their COVID-19 vaccine candidate, following setbacks …
ONK and Anthony Nolan combine forces to work on blood cancer therapies
February 22, 2021Sales and Marketing Anthony Nolan, Cancer, ONK, blood cancer, cancer treatment
ONK Therapeutics and blood cancer charity Anthony Nolan will work together on therapies for patients with haematological malignancies (blood cancers) …
MaxiVAX and Minaris sign manufacturing deal for cell-based cancer immunotherapy
February 22, 2021Sales and Marketing Cancer, MaxiVAX, Minaris
MaxiVAX and Minaris Regenerative Medicine have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of …
AstraZeneca to withdraw Imfinzi US indication for bladder cancer
February 22, 2021Sales and Marketing AstraZeneca, Imfinzi
AstraZeneca will voluntarily withdraw the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or …
Seagen’s breast cancer drug TUKYSA gets UK approval
February 22, 2021Sales and Marketing Cancer, MHRA, Seagen
The MHRA has granted marketing authorisation in the UK for Seagen’s TUKYSA (tucatinib) in combination with trastuzumab and capecitabine, for …
Pharmafile.com’s top 10 news stories of the week
February 19, 2021Medical Communications COVID-19, COVID-19 vaccine, Vaccine, pharma news, top 10, top news stories
In the last week, a number of COVID-19 new vaccine developments have been made. Pfizer and BioNTech’s vaccine has proven …
New Cell Guidance technology has potential to help treat cancer
February 19, 2021Medical Communications Cancer, cancer treatment, cell guidance systems, macrophages, pharma news
Cell Guidance Systems’ new POlyhedrin Delivery System (PODS) technology has been shown to have therapeutic potential in the treatment of …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
